Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN–JDRF Type 1 Diabetes Combination Therapy Assessment Group

摘要: Like many other complex human disorders of unknown aetiology, autoimmune-mediated type 1 diabetes may ultimately be controlled via a therapeutic approach that combines multiple agents, each with differing modes action. The numerous advantages such strategy include the ability to minimize toxicities and realize synergies enhance prolong efficacy. recognition combinations might offer far-reaching benefits, at time when few single agents have yet proved themselves in well-powered trials, represents significant challenge our conceive implement rational treatment designs. As first step this process, Immune Tolerance Network, collaboration Juvenile Diabetes Research Foundation, convened Type Combination Therapy Assessment Group, recommendations which are discussed Perspective paper.